Artisan Partners Limited Partnership Uni Qure N.V. Transaction History

Artisan Partners Limited Partnership

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$20.24 - $36.01 $1.25 Million - $2.23 Million	-61,990 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$26.01 - $38.22 $7 Million - $10.3 Million	-269,266 Reduced 81.29%	61,990 $1.98 Million
Q2 2021 Aug 12, 2021	SELL	$29.97 - $37.17 $1.21 Million - $1.51 Million	-40,518 Reduced 10.9%	331,256 $10.2 Million
Q1 2021 May 11, 2021	BUY	$29.24 - $42.03 $309,534 - $444,929	10,586 Added 2.93%	371,774 $12.5 Million
Q4 2020 Feb 10, 2021	SELL	$35.35 - $50.67 $83,319 - $119,429	-2,357 Reduced 0.65%	361,188 $13.1 Million
Q3 2020 Nov 12, 2020	BUY	$35.98 - $47.66 $938,610 - $1.24 Million	26,087 Added 7.73%	363,545 $13.4 Million
Q2 2020 Aug 12, 2020	SELL	$45.06 - $67.74 $683,605 - $1.03 Million	-15,171 Reduced 4.3%	337,458 $15.2 Million
Q1 2020 May 12, 2020	BUY	$40.01 - $73.97 $4.31 Million - $7.96 Million	107,635 Added 43.93%	352,629 $16.7 Million
Q4 2019 Feb 12, 2020	BUY	$37.13 - $74.62 $9.1 Million - $18.3 Million	244,994 New	244,994 $17.6 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Artisan Partners Limited Partnership with notifications on news.